España
India
Italia
대한민êµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Recent
Markets
Shibani Malhotra
Allergan Now Trades Cheaper Than Its Standalone Value
Endo's Selloff An 'Overreaction,' Nomura Says
Nomura Downgrades Valeant, Says It's Been 'Humbled'
Endo's Selloff An 'Overreaction,' Nomura Says
Nomura Downgrades Valeant, Says It's Been 'Humbled'
These Four Analysts Remain Bullish On Valeant
5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm
These Four Analysts Remain Bullish On Valeant
5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm
Actavis' Growth 'Underappreciated,' Sterne Agee Says
Sterne Agee Analyst: Court Win To Boost Net At Teva Pharmaceutical
Read More...
Shibani Malhotra Recent News
UPDATE: Sterne Agee Upgrades Teva Pharmaceutical
Sterne Agee Says Salix Pharmaceuticals Accounting Concerns Are 'Overdone'
Sterne Agee Sees Entry Point In Endo International PLC Shares
Sterne Agee Still Has Confidence In Actavis plc
Sterne Agee Raises Actavis plc Estimates, Price Target
Sterne Agee Adjusts Estimates For Salix Pharmaceuticals
Sterne Agee Feels More Positive On Allergan Following Recent Call With CEO
UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ltd. On FDA Panel Outcome
UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ahead Of FDA Panel Vote
UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ltd. On Upcoming Catalysts
UPDATE: Sterne Agee Reiterates On Actavis PLC On Good Market Position
Sterne Agee Believes Allergan Is In Stronger Position Than Originally Thought
Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries Ltd.
Sterne Agee Sees Good Things Ahead for Endo International PLC
Sterne Agee Expects Allergan to Resist Hostile Takeover by Valeant
Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage
Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing